Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
June 12, 2023 07:30 ET
|
Vaccitech plc
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
June 15, 2020 08:00 ET
|
Navidea Biopharmaceuticals, Inc.
DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...
Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2
August 29, 2019 13:53 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as...
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
August 26, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today positive results from a pilot clinical trial...
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
August 05, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) together with The Right to Try Foundation announced filing of a...
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
July 29, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported today positive animal data demonstrating synergy at...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
July 29, 2019 08:00 ET
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
July 22, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc. (OTC Markets: TSOI) reported today positive animal data demonstrating synergy...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 04, 2019 08:00 ET
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...